S100A6 and cancer: The preference of SRC3 to bind PR-A gives us reason to believe this interaction could be a primary cause for why excess PR-A leads to worse outcomes in breast cancer, considering SRC3 is an independent cancer driver currently being targeted for therapeutics.66